Neurotransmitter Changes by Interferon-Alpha and Therapeutic Implications

Pharmacopsychiatry

Volumn 36, Issue SUPPL. 3, 2003, Pages

  Schaefer, M ^a   Schwaiger, M ^a   Pich, M ^a   Lieb, K ^b   Heinz, A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cytokines; Dopamine; Glutamate; IFN ; Interferon alpha; Neurotransmitter; Opoid receptors; Serotonin

Indexed keywords

ADRENALIN; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; BETA INTERFERON; DEXAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR; GAMMA INTERFERON; GLUTAMATE RECEPTOR; INTERLEUKIN 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; NALTREXONE; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OPIATE ANTAGONIST; OPIATE RECEPTOR; PAROXETINE; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

CATALEPSY; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; CORRELATION ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG POTENTIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PARANOID PSYCHOSIS; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SIDE EFFECT; SUICIDAL BEHAVIOR; VIRUS INFECTION;

ANIMALS; CONFUSION; DEPRESSION; DOPAMINE; GLUTAMIC ACID; HUMANS; INTERFERON-ALPHA; NARCOTIC ANTAGONISTS; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PARANOID DISORDERS; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, OPIOID; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SUICIDE;

EID: 0345742596     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Abe S, Hori T, Suzuki T, Baba A, Shiraishi H, Yamamoto T. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res 1999; 24: 359-363
2. Blalock JE, Smith EM. Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activity. Biochem Biophys Res Commun 1981; 101 (2): 472-478
3. Brown RR, Lee CM, Kohler PC, Hank JA, Storer BE, Sondel PM. Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2. Cancer Res 1989; 49: 4941-4944
4. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7: 468-473
5. Chao CC, Hu S, Sheng WS, Bu D, Bukrinsky Ml, Peterson PK. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 1996; 16: 276-284
6. Dafny N. Interferon: a candidate as the endogenous substance preventing tolerance and dependence to brain opioids. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8: 351-357
7. Dafny N, Prieto-Gomez B, Dong WQ, Reyes-Vazquez C. Interferon modulates neuronal activity recorded from the hypothalamus, thalamus, hippocampus, amygdala and the somatosensory cortex. Brain Res 1996; 734: 269-274
8. Dafny N, Prieto-Gomez B, Reyes-Vazquez C. Does the immune system communicate with the central nervous system? Interferon modifies central nervous activity. J Neuroimmunol 1985; 9: 1-12
9. Dafny N, Reyes-Vazquez C. Three different types of alpha-interferons alter naloxone-induced abstinence in morphine-addicted rats. Immunopharmacology 1985; 9: 13-17
10. Dafny N, Zielinksi M, Reyes-Vazquez C. Alteration of morphine withdrawal to naloxone by interferon. Neuropeptides 1983; 3: 453-463
11. De La GR, Asnis GM. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res 2003; 977: 70-79
12. De Sarro GB, Masuda Y, Ascioti C, Audino MG, Nistico G. Behavioural and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by naloxone. Neuropharmacology 1990; 29: 167-179
13. Garssadi SI, Mandi Y, Regely K, Tarodi B, Beladi I. The inhibitory effect of interferon-alpha on the serotonin-induced impairment of human NK cell activity in whole blood. Brain Behav Immun 1993; 7: 164-175
14. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942-947
15. Heinz A, Schmidt LG, Reischies FM. Anhedonia in schizophrenic, depressed, or alcohol-dependent patients-neurobiological correlates. Pharmacopsychiatry 1994; 27 Suppl 1: 7-10
16. Ho BT, Huo YY, Lu JG, Tansey LW, Levin VA. Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-alpha. Pharmacol Biochem Behav 1992; 42: 57-60
17. Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation 2000; 7: 153-159
18. Jiang CL, Son LX, Lu CL, You ZD, Wang YX, Sun LY et al. Analgesic effect of interferon-alpha via mu opioid receptor in the rat. Neurochem Int 2000; 36: 193-196
19. Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 2000; 10: 129-132
20. Kamei S, Tanaka N, Mastuura M, Arakawa Y, Kojima T, Matsukawa Y et al. Blinded, prospective, and serial evaluation by quantitative-EEG in interferon-alpha-treated hepatitis-C. Acta Neurol Scand 1999; 100: 25-33
21. Katafuchi T, Take S, Hori T. Roles of cytokines in the neural-immune interactions: modulation of NMDA responses by IFN-alpha. Neurobiology (Bp) 1995; 3: 319-327
22. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1091-1099
23. Kraus MR, Schafer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 2001; 345: 375-376
24. Kumai T, Tateishi T, Tanaka M, Watanabe M, Shimizu H, Kobayashi S. Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. Life Sci 2000; 67: 663-669
25. Kuriyama K, Hori T, Mori T, Nakashima T. Actions of interferon alpha and interleukin-1 beta on the glucose-responsive neurons in the ventromedial hypothalamus. Brain Res Bull 1990; 24: 803-810
26. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88: 760-761
27. Makino M, Kitano Y, Komiyama C, Hirohashi M, Kohno M, Moriyama M et al. Human interferon-alpha induces immobility in the mouse forced swimming test: involvement of the opioid system. Brain Res 2000; 852: 482-484
28. Makino M, Kitano Y, Komiyama C, Hirohashi M, Takasuna K. Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test. Br J Pharmacol 2000; 130: 1269-1274
29. Mendoza-Fernandez V, Andrew RD, Barajas-Lopez C. Interferon-alpha inhibits long-term potentiation and unmasks a long-term depression in the rat hippocampus. Brain Res 2000; 885: 14-24
30. Menkes DB, MacDonald JA. Interferons, serotonin and neurotoxicity. Psychol Med 2000; 30: 259-268
31. Menzies RA, Patel R, Hall NR, O'Grady MP, Rier SE. Human recombinant interferon alpha inhibits naloxone binding to rat brain membranes. Life Sci 1992; 50: L227-232
32. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672-676
33. Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998; 349: 317-324
34. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-966
35. Nakashima T, Murakami T, Murai Y, Hori T, Miyata S, Kiyohara T. Naloxone suppresses the rising phase of fever induced by interferon-alpha. Brain Res Bull 1995; 37: 61-66
36. Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 781-823
37. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995; 45: 947-950
38. Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 731-746
39. Schafer M, Schmidt F, Amann B, Schlosser S, Loeschke K, Grunze H. Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000; 42 Suppl 1: 43-45
40. Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, Schmidt LG, Heinz A. Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Pharmacopsychiatry 2001; 34: 66-72
41. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173: 359-361
42. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997; 747: 348-351
43. Sugiyama K, Brunori A, Mayer ML. Glial uptake of excitatory amino acids influences neuronal survival in cultures of mouse hippocampus. Neuroscience 1989; 32: 779-791
44. Suter CC, Westmoreland BF, Sharbrough FW, Hermann RC, Jr. Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clin Proc 1984; 59: 847-850
45. Tachikawa E, Kondo Y, Takahashi M, Kashimoto T, Yanagihara N, Toyohira Y et al. Interferon-alpha reduces catecholamine secretion from bovine adrenal chromaffin cells stimulated by acetylcholine. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 699-705
46. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065-1069
47. Valentine AD, Meyers CA. Successful treatment of interferon-alpha- induced mood disorder with nortriptyline. Psychosomatics 1995; 36: 418-419
48. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995; 13: 561-566
49. Wang YX, Jiang CL, Lu CL, Song LX, You ZD, Shao XY et al. Distinct domains of IFNalpha mediate immune and analgesic effects respectively. J Neuroimmunol 2000; 108: 64-67
50. Yamano M, Yuki H, Yasuda S, Miyata K. Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J Pharmacol Exp Ther 2000; 292: 181-187